WOBURN, Mass.--(BUSINESS WIRE)--Dec. 2, 2003--Linden Bioscience today introduced a new protein identification service designed to provide research organizations with access to state-of-the-art informatics systems, novel scientific techniques, and project-dedicated scientists. Strategic Proteomic Services(TM) leverages Linden Bioscience's multi-million dollar proteomics program investment - in support of the company's integrated biomarker discover platform - over the past year.
The service features state-of-the-art analysis coupled with rapid, comprehensive protein identification through tightly-integrated informatics systems and processes. At the heart of the service are the ABI 4700 Proteomics Analyzer (MALDI TOF/TOF(TM)) and QSTAR® XL (LC/MS/MS) mass spectrometer systems. As part of the service, Linden Bioscience is providing direct access to project-dedicated company researchers. The company's scientists have optimized methods to maximize recovery from silver-stained protein gel samples (which contain only trace amounts of protein), as well as Coomassie and SYPRO Ruby techniques, while minimizing contamination. The service leverages the company's bioinformatics systems and resources to provide the annotation for detected proteins. Optionally, organizations can have Linden Bioscience researchers run 1D and 2D gel electrophoresis with or without mass spectrometry services.
Strategic Proteomic Services also features Functional Tissue Microdissection (FTM), a novel method developed by Linden Bioscience partner, TransMedix, for gathering single cells or small collections of cells. When coupled with FTM, Strategic Proteomic Services allow researchers to utilize highly-purified, disease-specific tissues in identifying potentially novel biomarkers or targets expressed in the particular disease. FTM relies on tumor and normal tissue to be collected at the time of the surgery so that it can be frozen in liquid nitrogen and stored until dissected. This process maximizes the recovery of intact protein and RNA while preserving histology for the technique. Recent publications have demonstrated the value of microdissection techniques, such as FTM, on the quantitation of genes expressed in diseased versus normal tissues.
With its Strategic Proteomic Services, Linden Bioscience is primarily targeting non-commercial research organizations, those that have intensive, yet periodic, protein profiling needs. For such organizations, it is more attractive to outsource than make a steep investment in high-end proteomics systems. Overall, the service is for organizations studying protein structure and function in normal and diseased tissues to shed light on potential drug targets and biomarkers.
"We have been building up our proteomics program and perfecting protein identification processes over the past year," said Dr. Beverly Brown, vice president of business development at Linden Bioscience. "We are now pleased to offer research organizations an attractively priced and highly-personalized protein identification service that leverages leading-edge informatics systems and techniques."
About Linden Bioscience
Linden Bioscience rapidly integrates cutting-edge technology in functional genomics, proteomics, bioinformatics and computational biology into an Applied Systems Biology(TM) technology platform. The company uses this platform to discover and validate disease biomarkers, targets and therapeutics. Through its Applied Systems Biology approach, the company's vision is to - on its own and with partners - rapidly develop drugs with greater efficacy and safety as compared to those developed using traditional processes. Additional information may be found at www.lindenbioscience.com.
Strategic Proteomic Services and Applied Systems Biology are trademarks of Linden Bioscience. QSTAR is a registered trademark and TOF/TOF is a trademark of Applera Corporation or its subsidiaries in the U.S. and certain other countries. All other trademarks are the property of their respective owners.
SunBridge Communications Bill Perkins, 617-448-5534 email@example.com
Source: Linden Bioscience